We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Vircell Highlights All-in-One CLIA System and Real Time PCR Kits

By LabMedica International staff writers
Posted on 13 Nov 2023

Image: VirClia LOTUS offers an unmatched infectious diseases menu in CLIA (Photo courtesy of Vircell)

Image: VirClia LOTUS offers an unmatched infectious diseases menu in CLIA (Photo courtesy of Vircell)

Vircell (Granada, Spain) is highlighting the VirClia LOTUS CLIA analyzer at MEDICA 2023, the world's largest event for the medical sector. The VirClia LOTUS fully automated random access and continuous loading CLIA analyzer marks a revolution in infectious serology by offering the benefit of any test, any sample, any time. The analyzer allows to run more than 90 infectious markers in a monotest format with total flexibility and no need for reagents on board. The first results are available within 70 minutes and then, every 35 seconds thereafter.

VirClia Lotus accepts any combination of samples and reagents, regardless of the instrument status. Even while running, it remains accessible for reagent and sample addition. Urgent samples can be prioritized. With VirClia Lotus, STAT test requests are given the highest priority for processing. This true monotest solution allows the laboratory to run esoteric and low-volume infectious serology tests daily, alongside the laboratory routine. VirClia Lotus unifies in just one CLIA system, all those parameters are typically performed with ELISA, IFA, or Rapid Tests.

The instrument’s built-in scanner allows for full traceability of both samples and strips, avoiding clerical errors. Labs can save hands-on time using primary tubes (11-16 mm) directly in VirClia Lotus, avoiding the inconvenience of transferring samples or performing external predilution. VirClia Lotus offers the widest panel for infectious serology in CLIA, continuous loading, and multi-batch testing to run any number of different VirClia parameters simultaneously.

Related Links:
Vircell

Visit expo >

New

Gold Member

Neonatal Heel Incision Device

Tenderfoot

New

Gold Member

STI Test

Vivalytic MG, MH, UP/UU

New

Multi-Chamber Washer-Disinfector

WD 390

New

POC Immunoassay Analyzer

Procise DX

Latest Medica 2023 News

Channels

Clinical Chemistry

view channel

Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms

Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more

Image: ApoB is a blood test that counts the total number of harmful particles in circulation, providing a more complete assessment of risk (photo courtesy of Adobe Stock)

Study Finds ApoB Testing More Effective Than LDL for Guiding Lipid Therapy

Routine blood tests that measure low-density lipoprotein (LDL), commonly known as “bad” cholesterol, are widely used to guide lipid-lowering therapy, but they do not always provide a complete picture of... Read more

Image: Overview of the dual-mode xVFA optical sensor platform for multiplexed cardiac biomarker detection in point-of-care settings (Han, GR., Eryilmaz, M., Goncharov, A. et al. Light Sci Appl 15, 190 (2026). doi.org/10.1038/s41377-026-02275-9)

AI-Enabled POC Test Quantifies Multiple Cardiac Biomarkers

Cardiovascular diseases are a leading cause of death, responsible for nearly 20 million deaths each year. Timely triage of myocardial infarction and heart failure hinges on rapid cardiac biomarker measurement,... Read more

Next Generation Automated Analyzers Increase Throughput for Clinical Chemistry and Electrolyte Testing

Clinical laboratories continue to face staffing shortages, limited space, and growing test volumes that pressure chemistry and electrolyte workflows. Maintaining rapid turnaround times increasingly depends... Read more

Molecular Diagnostics

view channel

Ultrasensitive Assay Reveals Previously Undetected Tuberculosis in Hospital Patients

Tuberculosis remains the leading cause of death from an infectious disease worldwide, and diagnosis can be difficult when bacterial load is low or disease is atypical. In the United States, the disease... Read more

Study Confirms Barrett’s Esophagus as Precursor to Esophageal Cancer

Esophageal adenocarcinoma is rising in Western countries and is often detected late, limiting treatment options. Clinicians suspect many cases begin in Barrett’s esophagus, yet the precursor lesion is... Read more

Urine-Based Assay Predicts Severe Dengue Risk Early

Dengue is among the most widespread mosquito-borne infections, yet early risk stratification can be difficult when symptoms overlap with other febrile illnesses. Only about 2% to 5% of patients develop... Read more

CE-Marked Blood Test Enables Monitoring of Neuroinflammation in Multiple Sclerosis

Multiple sclerosis affects more than 2.9 million people worldwide and requires ongoing evaluation of disease activity to guide care. Routine monitoring often depends on magnetic resonance imaging (MRI),... Read more

Hematology

view channel

Routine Blood Test Parameters Link Anemia to Cancer Risk and Mortality

Anemia detected in routine care can signal underlying pathology and is frequently encountered in adults. Because it is defined by hemoglobin levels below the normal range, it is often evaluated with red... Read more

Prognostic Tool Guides Personalized Treatment in Rare Blood Cancer

Chronic myelomonocytic leukemia (CMML) is a rare blood cancer in which acquired genetic mutations in bone marrow stem cells drive disease. Stem cell transplantation is the only curative option but carries... Read more

New Platelet Function Assay Enables Monitoring of Antiplatelet Therapy

Monitoring response to antiplatelet therapy remains challenging for many clinical laboratories. Aggregation-based assays and cartridge systems often require specialized personnel, dedicated instruments,... Read more

Open Multi-Omics Platform Identifies Prognostic Subtypes in Blood Cancers

Blood cancers encompass diverse entities whose biology and clinical behavior are best understood through integrative analyses across large cohorts. However, multi‑omic datasets and outcomes information... Read more

Immunology

view channel

Study Finds Influenza Often Undiagnosed in Winter Deaths

Seasonal influenza drives substantial excess mortality, yet its contribution is often obscured when infections go undiagnosed near the time of death. Many deaths occur outside hospitals or in older adults... Read more

Combined Screening Approach Identifies Early Leprosy Cases

Leprosy remains a significant public health concern, with more than 200,000 new cases reported globally each year and early disease often escaping routine laboratory detection. In its initial phase, bacterial... Read more

Image: Mycobacterium tuberculosis bacteria seen with a scanning electron microscope (Credit: CDC PHIL)

Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection

Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. Standard screening tools... Read more

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more

Microbiology

view channel

Syndromic Panel Enables Rapid Identification of Bloodstream Infections

Bloodstream infections require rapid identification of causative pathogens and resistance determinants to guide therapy, yet laboratories often face pressure to deliver clinically relevant results quickly... Read more

RNA-Based Workflow Identifies Active Skin Microbes for Dermatology Research

Human skin carries diverse microbial communities that influence barrier function and inflammation, yet identifying which organisms are metabolically active has been challenging. DNA-based surveys catalog... Read more

Cost-Effective Sampling and Sequencing Workflow Identifies ICU Infection Hotspots

Intensive care units face persistent threats from hospital-acquired infections, increasingly driven by drug-resistant bacteria. Rapidly pinpointing environmental reservoirs and transmission hotspots remains... Read more

New Bacterial Target Identified for Early Detection of Noma

Noma is a rapidly progressing orofacial infection that begins as gingivitis and can destroy oral and facial tissues, primarily affecting young children living in extreme poverty. Without treatment, it... Read more

Pathology

view channel

Biomarker Predicts Immunotherapy Response and Prognosis in Colorectal Cancer

Colorectal cancer is common and often lethal, and therapeutic decision-making is complicated by heterogeneous tumor microenvironments. Immunotherapy benefits only a small subset of patients, around 5%,... Read more

Collaboration Applies AI Pathology to Predict Response to Antibody-Drug Conjugates

Antibody-drug conjugates (ADC) are reshaping oncology, yet scalable biomarkers that reliably predict which patients will benefit remain limited as treatment regimens and combinations grow more complex.... Read more

AI Improves Completeness of Complex Cancer Pathology Reports

Oncology teams increasingly rely on pathology reports that integrate histopathology, immunohistochemistry, and rapidly expanding biomarker testing. As patients live longer and undergo repeated analyses... Read more

AI Tool Predicts Chemotherapy Response in Small Cell Lung Cancer

Small cell lung cancer often presents at an extensive stage and progresses rapidly, leaving little time to tailor first-line therapy. Clinicians currently lack biomarkers to guide which patients will benefit... Read more

Technology

view channel

AI Tool Predicts Non-Response to Targeted Therapy in Colorectal Cancer

Advanced bowel cancer remains difficult to treat, and many patients receive targeted therapies that do not help them but still cause harm. Clinicians need reliable ways to identify likely responders before... Read more

Integrated System Streamlines Pre-Analytical Workflow for Molecular Testing

Pre-analytical variation remains a leading source of inconsistent molecular test results and added costs, particularly when laboratories rely on multiple instruments and protocols. Standardizing nucleic... Read more

Noninvasive Sputum Test Detects Early Lung Cancer

Early detection remains critical for improving outcomes in lung cancer, yet clinicians increasingly encounter indeterminate pulmonary nodules found incidentally or through screening, complicating decision-making.... Read more

Image: Graphical Abstract (Huiqian Hu et al., Med 7(3): 100966 (2026). DOI: 10.1016/j.medj.2025.100966)

New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia

Children with T-cell acute lymphoblastic leukemia face an aggressive disease that remains difficult to treat. Although remission rates have improved, many survivors experience long-term effects from intensive... Read more

Industry

view channel

Beckman Coulter Gains CE Mark for Rapid Assay Distinguishing Bacterial vs Viral Infections

Clinicians often struggle to distinguish bacterial from viral infections at first presentation because symptoms overlap and definitive culture or molecular results can take hours or days.... Read more

Junction, GRAIL Enable Scalable Access to Multi-Cancer Detection Test

Junction has announced a collaboration with GRAIL to enable broad access to the Galleri multi-cancer early detection (MCED) blood test across digital health platforms and clinical organizations.... Read more

GRAIL Partners with Epic to Integrate Multi-Cancer Test into EHR

GRAIL’s Galleri multi-cancer early detection (MCED) test is being integrated into Epic’s electronic health record (EHR) platform through Epic Aura. The collaboration is designed to let clinicians at interested... Read more

Global Partnership Aims to Streamline NGS Tumor Profiling in Oncology Trials

CellCarta and Pillar Biosciences announced a global, multi-year strategic partnership on April 2, 2026 to broaden access to operationally streamlined next-generation sequencing (NGS) tumor profiling for... Read more